| Customization: | Available |
|---|---|
| Transport Package: | Drum |
| Specification: | 99% |
|
Still deciding? Get samples of US$ 50/Piece
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Escitalopram oxalate is a selective serotonin reuptake inhibitor (SSRI) indicated for the acute and maintenance treatment of major depressive disorder (MDD) in adults and adolescents aged 12 to 17 years. It is also used for the acute treatment of Generalized Anxiety Disorder (GAD) in adults. The mechanism of action is believed to be linked to potentiation of serotonergic activity in the central nervous system (CNS), resulting from its inhibition of CNS neuronal reuptake of serotonin (5-HT). Escitalopram is the pure S-enantiomer of the racemic compound citalopram and is at least 100-fold more potent than the R-enantiomer in inhibiting 5-HT reuptake.
The recommended dosage for MDD in adults is 10 mg once daily, which can be increased to 20 mg after a minimum of one week. For adolescents, the same dosage applies. In the treatment of GAD, the recommended starting dose for adults is also 10 mg once daily, with the possibility of increasing to 20 mg after a minimum of one week. Escitalopram oxalate is generally well-tolerated, with common side effects including nausea, insomnia, fatigue, and sexual dysfunction. It is important to note that escitalopram oxalate is not approved for use in pediatric patients less than 12 years of age.
When discontinuing treatment with escitalopram oxalate, it is recommended to taper the dose rather than stopping abruptly to minimize withdrawal symptoms. There are also precautions regarding the potential for serotonin syndrome when co-administered with other serotonergic drugs, and the risk of abnormal bleeding when used with NSAIDs, aspirin, warfarin, or other drugs affecting coagulation.
Escitalopram oxalate is contraindicated with monoamine oxidase inhibitors (MAOIs), and at least 14 days should elapse between discontinuation of an MAOI and initiation of escitalopram oxalate therapy. It is also contraindicated in patients with known hypersensitivity to escitalopram or citalopram.
In overdose, symptoms can include convulsions, coma, hypotension, and ECG changes. Management of overdose includes establishing and maintaining an airway, gastric evacuation, and monitoring of vital signs. There are no specific antidotes for escitalopram oxalate.
){kind=link}